Cornea

The retrospective study assessed corneal cross-linking complications at Wills Eye Hospital from 2018 to 2023.

New research links HPV to thyroid eye disease, suggesting viral infection may trigger immune responses through molecular mimicry, impacting diagnosis and treatment.

George O. Waring IV, MD, FACS, discusses the “vision for a lifetime” approach and how modern advancements allow tailored treatments for every stage of eye maturity.

Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.

A five-step approach to personalise and simplify treatment, leading to higher efficacy

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)

Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Epi-on corneal crosslinking is advancing through innovations like supplemental oxygen, chemical oxygenation, and laser-assisted techniques.

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal endothelial disease.

Vision correction has evolved into a continuum of procedures suited for different stages of ocular maturity

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

The study findings indicated that lifestyle changes associated with the COVID-19 pandemic were connected to an increase in childhood astigmatisms.

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed them for 18 months.

The system aids in the orthokeratology lens design process by syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds.

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug.

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set